Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Launched in October 2016, Big Drop Brewing is a world-leading alcohol-free craft brewer. The company brews beer naturally by using specialist brewing methods to ensure the alcohol never exceeds 0.5%. The beer is not only Alcohol-Free, but is also gluten-free and many are low in sugar. Their award-winning lager is vegan-friendly. The company does not have a brewery of its own but partners with reputable breweries around the world, who share their brewing values to produce the beer. Big Drop Brewing has secured private funding already and meaningful distribution in the UK and 12 overseas markets. They have also secured off-trade listings in Tesco, Morrisons and Ocado. Half of the investment will be used for Sales & Marketing, 30% for new branding launch and related marketing, 10% for production costs and the remaining 10% for product development.
days to go:
Expired
investment:
£617,566
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go:
Expired
investment:
Withheld
Swoopos is a mobile point of sale system, which brings together innovative software and hardware, cloud reporting and data analytics, mobile and ecommerce ordering and beacon marketing technology for retail, hospitality and stadiums. Swoops have already built long term relationships with leading brands and are now looking to expand throughout the UK and beyond.
days to go:
Expired
investment:
£64,480
Swing has pioneered an IoT-connected micro-gym, the Swing Box, equipped with integrated free weights suitable for outdoor use. This innovative gym solution includes adjustable backrests and various dumbbells and kettlebells, catering to users of all fitness levels. Users can conveniently locate, reserve, and unlock the Swing Box using any smartphone, aiming to combat physical inactivity, which contributes to a significant number of deaths and costs the UK £7.4 billion annually. Swing's solution addresses the barriers of affordability, accessibility, and time in exercise by providing on-demand, free-access outdoor micro-gyms in communal parks and green spaces. With over 90% of UK residents within a 10-minute walk of public parks and only 32% meeting NHS guidelines for muscle-strength activity, Swing aims to lease these boxes to grant public access with leaseholders paying an annual fee of £2500 per box, covering maintenance and operations.
days to go:
Expired
investment:
£287,590
SRSLY Low Carb, an award-winning health food brand, specializes in high protein, low carb products to make healthy eating both convenient and delicious. They've already played a significant role in 4.5 million meals and generated over £6 million in revenue, boasting an impressive 79% repeat order rate and a 35% subscription rate. With a recent NHS England contract and the first US retail order secured, SRSLY is poised to expand into local and international retail markets with the ambition of becoming a global leader in the field. They've demonstrated market fit with customers reporting benefits like longer satiation for weight loss and better blood sugar control for those with diabetes. As 70% of adults seek healthier food options, SRSLY sees abundant opportunities to meet customer needs and empower families to make convenient, healthy, and tasty food choices.
days to go:
Expired
investment:
£274,197
